Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akari Therapeutics PLC

akaritx.com

Latest From Akari Therapeutics PLC

Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.

 

Blood & Coagulation Disorders Clinical Trials

Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board of directors, other execs join Merck, Apeiron Biologics, Vectura, Roivant, OncoSec, Breath Therapeutics, Immusoft and M3 Biotechnology.

Appointments BioPharmaceutical

Pipeline Watch – Updates From EULAR, EHA and ECNP

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Clinical Trials

Pipeline Watch: Peficitinib, Ubrogepant, Apalutamide Phase III Read-Outs

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Morria Biopharmaceuticals PLC
  • Celsus Therapeutics PLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akari Therapeutics PLC
  • Senior Management
  • Clive Richardson, CEO
    Dov Elefant, CFO
    Miles Nunn, CSO
  • Contact Info
  • Akari Therapeutics PLC
    Phone: (44)(646) 350-0702
    24 West 40th St.
    8th Fl.
    New York, 10018
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register